<DOC>
	<DOCNO>NCT02564926</DOCNO>
	<brief_summary>To evaluate effect dapagliflozin body composition Korean T2DM subjects.12-month , randomise , open-label , parallel-group , multi-centre phase IV study .</brief_summary>
	<brief_title>Foxiga Korea Local Phase 4 Study</brief_title>
	<detailed_description>This 52 week , randomize , open-label , parallel-group , multi-centres phase IV study . Participants randomize 1:1 receive dapagliflozin 10 mg qd glimepiride 1~2 mgqd open-label manner 12 month add-on metformin 1000 mg . Parallel group study design chosen . In order maintain practicality phase IV study , open label design study drug delivery chosen . The reading DXA scan conduct one expert blind manner . Glimepiride frequently use SUs Korea therefore choose comparator.Dapagliflozin treatment associate reduction total body FM , BW , abdominal VAT SAT volume compare glimepiride .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Adults T2DM ( Male female , ≥ 19 ≤ 75 yr ) 2 . Patients insufficient glycemic control ( HbA1c &gt; 7.5 % &lt; 9.5 % recent 4 week ) 3 . Patients unchanged dose metformin ( ≥ 1,000 mg/day ) &gt; 8 week prior randomization 4 . Written inform consent 5 . WOCBP must take precaution avoid pregnancy throughout study 4 week intake last dose . WOCBP must negative urine pregnancy test screen visit WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . WOCBP must willing use medically accept method contraception consider reliable judgment Investigator . 1 . Type 1 diabetes history diabetic ketoacidosis 2 . Pregnant breastfeeding patient 3. eGFR &lt; 60 mL/min/1.73 m2 ( MDRD ) visit 1 . 4 . Indication active liver disease ( AST/ALT/total bilirubin &gt; 3 X upper limit normal ) visit 1 . 5 . Acute coronary syndrome , stroke TIA within 3 month prior randomization 6 . Bariatric surgery within 2 year ; treatment antiobesity drug 3 month prior randomization ; treatment lead unstable body weight . ( Unstable body weight consider reliable judgment Investigator . ) 7 . History bladder cancer history radiation therapy low abdomen pelvis time 8 . History malignancy within 5 year ( exception successfully treat nonmelanoma skin cancer ) 9 . History alcohol drug abuse judge physician within 3 month prior randomization 10 . Concomitant participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DM</keyword>
</DOC>